Galedra
Sign in Sign up

Evidence item

The passage directly reports the specificity, episode sensitivity, descriptive-analysis caveat, and missed primary endpoint. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 16397

Source: Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial · locator {} · excerpt hash sha256:9438cd4c387f8986b0fc5b0503dd5ca3614ad0666291555a211e092b4812a108

Exact excerpt
Across rounds, specificity ranged from 99.50% to 99.60%; episode sensitivity ranged from 26.7% to 37.2% for all cancers ... These analyses were descriptive; there was no hypothesis testing. We reported elsewhere that the primary endpoint of a reduction in the incidence of stage III/IV cancer diagnoses ... was not met.

Linked claims

ClaimDirectionRelevanceStepsCounted
77512f4eSUPPORTDIRECT0yes

Audits

None.